

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

**VOLUNTARY ANNOUNCEMENT
IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE**

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on 16 February 2022, 14 March 2022 and 15 June 2022 in relation to the latest research and development progress of one of the Group’s key products, SM17.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 19 May 2023, an Investigational New Drug application (“**IND**”, for asthma) for SM17 has been filed with and accepted by the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of China (the “**NMPA**”). Upon approval of the present IND, the Company plans to initiate a Phase I clinical study in China to bridge between Chinese (Asian) and American (Caucasian/Black) populations, as well as to investigate the safety profile of SM17 in Chinese population. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of asthma.

SM17 is a humanized, IgG4-k monoclonal antibody targeting IL-17RB. SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as “alarmin”, which has shown to be implicated in the pathogenesis of airway viral responses and allergic disease, such as asthma. Patients with severe, uncontrolled asthma are at a risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality/morbidity, diminished quality of life and increased health expenditures. Current approved therapies for severe asthma, including biologics, can reduce asthma annual exacerbations to a certain extent. However, there is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. We expect that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB, will have a

broad effect on airway inflammation. We believe in the huge potential of SM17 to satisfy unmet medical needs in asthma treatment.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 22 May 2023

As at the date of this announcement, the executive director is Dr. Shui On LEUNG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU, Mr. Lei SHI, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.